Terra Alpha Investments LLC Takes $1.24 Million Position in IDEXX Laboratories, Inc. $IDXX

Terra Alpha Investments LLC bought a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 4th quarter, Holdings Channel reports. The firm bought 1,835 shares of the company’s stock, valued at approximately $1,241,000. IDEXX Laboratories accounts for about 1.3% of Terra Alpha Investments LLC’s portfolio, making the stock its 27th largest holding.

Several other large investors have also recently made changes to their positions in the business. EverSource Wealth Advisors LLC lifted its holdings in shares of IDEXX Laboratories by 2.5% during the third quarter. EverSource Wealth Advisors LLC now owns 621 shares of the company’s stock valued at $397,000 after purchasing an additional 15 shares during the last quarter. CWA Asset Management Group LLC lifted its holdings in shares of IDEXX Laboratories by 3.5% during the fourth quarter. CWA Asset Management Group LLC now owns 509 shares of the company’s stock valued at $344,000 after purchasing an additional 17 shares during the last quarter. Stratos Wealth Partners LTD. lifted its holdings in shares of IDEXX Laboratories by 1.7% during the third quarter. Stratos Wealth Partners LTD. now owns 1,069 shares of the company’s stock valued at $683,000 after purchasing an additional 18 shares during the last quarter. Cary Street Partners Investment Advisory LLC lifted its holdings in shares of IDEXX Laboratories by 11.5% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 174 shares of the company’s stock valued at $111,000 after purchasing an additional 18 shares during the last quarter. Finally, Rockland Trust Co. lifted its holdings in shares of IDEXX Laboratories by 4.4% during the fourth quarter. Rockland Trust Co. now owns 425 shares of the company’s stock valued at $288,000 after purchasing an additional 18 shares during the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $528.79 on Friday. IDEXX Laboratories, Inc. has a twelve month low of $496.61 and a twelve month high of $769.98. The firm has a market cap of $41.71 billion, a P/E ratio of 38.94, a PEG ratio of 3.10 and a beta of 1.58. The company has a 50 day moving average of $572.08 and a 200 day moving average of $645.56. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The company had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same period in the previous year, the business earned $2.91 EPS. The firm’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, research analysts expect that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Insider Activity

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 1,464 shares of IDEXX Laboratories stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total value of $920,299.68. Following the completion of the sale, the director owned 648 shares of the company’s stock, valued at approximately $407,345.76. The trade was a 69.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Jonathan Jay Mazelsky sold 23,326 shares of IDEXX Laboratories stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $657.55, for a total transaction of $15,338,011.30. Following the completion of the sale, the chief executive officer directly owned 83,606 shares of the company’s stock, valued at approximately $54,975,125.30. This trade represents a 21.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 34,612 shares of company stock valued at $22,525,070 in the last quarter. Insiders own 0.79% of the company’s stock.

Wall Street Analyst Weigh In

IDXX has been the subject of several recent research reports. UBS Group lowered their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. Stifel Nicolaus lowered their target price on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Citigroup began coverage on shares of IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 target price for the company. BTIG Research decreased their price objective on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. Finally, Piper Sandler decreased their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a report on Monday, February 9th. Seven investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, IDEXX Laboratories currently has an average rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.